Loading…
← CockpitCompetitor Analysis › 1951.HK Jinxin Fertility Group Ltd.Open in the cockpit ↗

Jinxin Fertility Group Ltd.1951.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Medical/Nursing Services
Momentum leader 81
Mkt cap
$758M
US dollars, full cap
Free float
82%
of shares outstanding
$/day
$2.87M
20-day average traded
Fwd P/E
23.1×
forward earnings
ROIC−WACC
-7.4 pp
WACC 9.7%
Hurdle
+5 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · HKDHK$2.25
1D+0.7%
1W-1.3%
1M+1.1%
3M+7.9%
6M-4.0%
YTD-5.2%
1Y-8.7%
ATR %3.2%
52w lowhigh15.5% off high

What Jinxin Fertility does

Employees: 3,494

Jinxin Fertility at a glance

Size Jinxin Fertility (1951.HK) is a Hong Kong Health Care company (Medical/Nursing Services) with a market value of $758M, the 650th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$2.25 on 18 Nov 2026.

Performance Over six months the shares fell 4.0%, against +0.9% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue grew 6.5% over the last twelve months (peer median +5.2%); the operating margin is 11.4% (peer median 6.8%).

Valuation It trades at 23.1× forward earnings against a peer median of 19.6× (7th most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 7.4 points below its cost of capital (9.7% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 1041951.HK 98
Six months, rebased to 100: Jinxin Fertility against the median of its 20 peers (local-currency closes).

Jinxin Fertility financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$3.05BHK$2.87BHK$3.05BHK$3.08BHK$2.75B
Revenue growth—-6%-1%+12%—
Gross profitHK$1.08BHK$911MHK$1.14BHK$1.25BHK$970M
EBITDAHK$739MHK$510MHK$780MHK$847MHK$591M
Net incomeHK$192M-HK$1.06BHK$307MHK$381MHK$141M
Free cash flowHK$254MHK$243MHK$268MHK$407M-HK$527M
Capital expenditureHK$267MHK$287MHK$284MHK$192MHK$1.12B
Total debtn/aHK$3.29BHK$2.89BHK$3.07BHK$5.00B

Quarterly statements and history in the cockpit →

Jinxin Fertility competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-20%0%+20%195940GMRSNEPHROPLUSFLGTTTALOTHYROCAREWELL4694REGAHCO688315DNA301060GDRXNUTXMETROPOLISOPK127120PNTGDIA1951.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Jinxin Fertility is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×195940GMRSNEPHROPLUSTTALOTHYROCAREWELL4694REG688315GDRXNUTXMETROPOLISPNTGDIA1951.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jinxin Fertility is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%195940GMRSNEPHROPLUSTHYROCAREWELL4694NUTXPNTG1951.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jinxin Fertility is the large dot.

Jinxin Fertility competitors and peer comparison

How Jinxin Fertility compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jinxin Fertility against its 20 peers (data as of 18 Nov 2026)
Measure1951.HKPeer medianRank in peer set
1-month return+1.1%-0.5%10th highest of 21
6-month return-4.0%+0.9%10th lowest of 21
Distance from 52-week high-15.5%-27.3%5th highest of 21
Revenue growth (TTM)+6.5%+5.2%10th highest of 21
Operating margin11.4%6.8%9th highest of 21
Forward P/E23.1×19.6×7th most expensive of 15
Growth the price implies (Req g, 7 yrs)17.8%8.7%5th most demanding of 17
Growth delivered (Del g)+12.4%+11.5%8th highest of 17
Hurdle (Req g minus delivered)+5.5 pp-4.9 pp4th most demanding of 17
ROIC minus cost of capital-7.4 pp+0.2 pp5th lowest of 20
EV / EBITDA11.6×8.5×6th most expensive of 15
Net debt / EBITDA3.4×1.6×3rd most indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%23.1×17.8%+12.4%
HK inno.N 195940.KSSouth Korea$783M-28%+7%12%12.3×-4.7%+12.2%
GMR Solutions GMRSUnited States$714M-8%-4%14%5.9×-19.6%-4.0%
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%48.8×36.6%+31.6%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%n/an/an/a
Terveystalo Oy TTALO.HEFinland$832M-26%-8%8%10.7×-5.1%+5.3%
Thyrocare Technologies THYROCARE.NSIndia$858M+7%+22%26%36.0×28.5%+10.9%
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%10.1×10.1%+94.5%
BML 4694.TJapan$932M+12%+4%7%19.8×-9.0%+1.6%
Regis Healthcare REG.AXAustralia$962M-28%+17%4%25.3×13.3%+14.4%
AdaptHealth AHCOUnited States$1.01B-30%-3%3%n/a16.8%+25.2%
Novogene 688315.SSChina$1.01B+13%+6%7%44.8×13.9%+8.2%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%n/an/an/a
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%n/a5.9%+3.2%
GoodRx GDRXUnited States$1.15B+33%-2%12%10.6×6.3%+7.7%
Nutex Health NUTXUnited States$1.19B+42%-19%39%6.5×-18.0%+253.5%
Metropolis Healthcare METROPOLIS.NSIndia$1.25B+11%+20%18%44.5×32.4%+10.5%
OPKO Health OPKUnited States$1.25B+37%-22%-29%n/an/an/a
JS Link 127120.KSSouth Korea$458M-62%+39%-83%n/an/an/a
Pennant PNTGUnited States$1.26B+1%+39%6%23.7×20.7%+19.4%
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%19.5×7.3%+18.9%

Questions

Which companies are Jinxin Fertility's closest peers?
The cockpit's peer set: HK inno.N (195940.KS), GMR Solutions (GMRS), Nephrocare Health Services (NEPHROPLUS.NS), Fulgent Genetics (FLGT), Terveystalo Oy (TTALO.HE), Thyrocare Technologies (THYROCARE.NS), WELL Health Technologies (WELL.TO), BML (4694.T).
Is Jinxin Fertility expensive compared with its peers?
On forward p/e it trades at 23.1× against a peer median of 19.6×, 7th most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Jinxin Fertility stock performed?
Over six months to 18 Nov 2026 the shares returned -4.0% against +0.9% for the median peer; over one year -8.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.